Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity
- PMID: 18243930
- DOI: 10.1016/j.ophtha.2007.10.009
Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity
Abstract
Topic: The incidence and morbidity of herpes zoster (HZ) and HZ ophthalmicus (HZO), and the potential impact of varicella vaccine on their epidemiology.
Clinical relevance: Herpes zoster affects 20% to 30% of the population at some point in their lifetime; approximately 10% to 20% of these individuals will have HZO.
Methods: The peer-reviewed literature published from 1865 to the present was reviewed.
Results: Herpes zoster is the second clinical manifestation of varicella-zoster virus (VZV). The incidence and severity of HZ increase with advancing age. Varicella-zoster virus-specific cell-mediated immunity, which keeps latent VZV in check and is boosted by periodic reexposure to VZV, is an important mechanism in preventing VZV reactivation as zoster. Thus, widespread varicella vaccination may change the epidemiology of HZ. Herpes zoster ophthalmicus occurs when HZ presents in the ophthalmic division of the fifth cranial nerve. Ocular involvement occurs in approximately 50% of HZ patients without the use of antiviral therapy. There is a long list of complications from HZ, including those that involve the optic nerve and retina in HZO, but the most frequent and debilitating complication of HZ regardless of dermatomal distribution is postherpetic neuralgia (PHN), a neuropathic pain syndrome that persists or develops after the zoster rash has resolved. The main risk factor for PHN is advancing age; other risk factors include severe acute zoster pain and rash, a painful prodrome, and ocular involvement. Many cases of HZ, HZO, and PHN can be prevented with the zoster vaccine.
Conclusion: Vaccination is key to preventing HZ, HZO, and PHN, but strategies for both varicella and HZ vaccines will need to be evaluated and adjusted periodically as changes in the epidemiology of these VZV diseases become more evident.
Similar articles
-
Management and Prevention of Herpes Zoster Ocular Disease.Cornea. 2015 Oct;34 Suppl 10:S3-8. doi: 10.1097/ICO.0000000000000503. Cornea. 2015. PMID: 26114827 Review.
-
Vaccination: a new option to reduce the burden of herpes zoster.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Expert Rev Vaccines. 2010. PMID: 20192716 Review.
-
Herpes zoster: epidemiology, natural history, and common complications.J Am Acad Dermatol. 2007 Dec;57(6 Suppl):S130-5. doi: 10.1016/j.jaad.2007.08.046. J Am Acad Dermatol. 2007. PMID: 18021864 Review.
-
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17. Vaccine. 2007. PMID: 17980938
-
A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.J Drugs Dermatol. 2006 Oct;5(9):863-6. J Drugs Dermatol. 2006. PMID: 17039651 Review.
Cited by
-
Abducens Nerve Palsy as a Rare Complication of Herpes Zoster Ophthalmicus: A Case Report.Cureus. 2024 Apr 3;16(4):e57506. doi: 10.7759/cureus.57506. eCollection 2024 Apr. Cureus. 2024. PMID: 38707108 Free PMC article.
-
Lacrimal Neuralgia: A Case Report and Comprehensive Review of the Literature.Curr Pain Headache Rep. 2024 Apr 27. doi: 10.1007/s11916-024-01250-6. Online ahead of print. Curr Pain Headache Rep. 2024. PMID: 38676822 Review.
-
Herpes Zoster Ophthalmicus Initially Diagnosed As Cluster Headache, Complicated by Delayed Eruption.Cureus. 2024 Mar 22;16(3):e56698. doi: 10.7759/cureus.56698. eCollection 2024 Mar. Cureus. 2024. PMID: 38646210 Free PMC article.
-
Radiofrequency regulation of the sphenopalatine ganglion in managing herpes zoster ophthalmicus neuralgia: A case series.Medicine (Baltimore). 2024 Apr 19;103(16):e37884. doi: 10.1097/MD.0000000000037884. Medicine (Baltimore). 2024. PMID: 38640323 Free PMC article.
-
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.Pharmacoecon Open. 2024 May;8(3):481-492. doi: 10.1007/s41669-024-00483-w. Epub 2024 Apr 11. Pharmacoecon Open. 2024. PMID: 38605257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical